110 related articles for article (PubMed ID: 1652468)
1. A novel strategy for converting recombinant viral protein into high immunogenic antigen.
Hinuma S; Hazama M; Mayumi A; Fujisawa Y
FEBS Lett; 1991 Aug; 288(1-2):138-42. PubMed ID: 1652468
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant-independent enhanced immune responses to recombinant herpes simplex virus type 1 glycoprotein D by fusion with biologically active interleukin-2.
Hazama M; Mayumi-Aono A; Asakawa N; Kuroda S; Hinuma S; Fujisawa Y
Vaccine; 1993; 11(6):629-36. PubMed ID: 8391739
[TBL] [Abstract][Full Text] [Related]
3. Intranasal immunization against herpes simplex virus infection by using a recombinant glycoprotein D fused with immunomodulating proteins, the B subunit of Escherichia coli heat-labile enterotoxin and interleukin-2.
Hazama M; Mayumi-Aono A; Miyazaki T; Hinuma S; Fujisawa Y
Immunology; 1993 Apr; 78(4):643-9. PubMed ID: 8388365
[TBL] [Abstract][Full Text] [Related]
4. Role of coexpression of IL-2 and herpes simplex virus proteins in recombinant vaccinia virus vectors on levels of induced immunity.
Allen EM; Weir JP; Martin S; Mercadal C; Rouse BT
Viral Immunol; 1990; 3(3):207-15. PubMed ID: 2175194
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
J Virol; 2017 May; 91(9):. PubMed ID: 28228587
[TBL] [Abstract][Full Text] [Related]
6. Virus neutralizing activity induced by synthetic peptides of glycoprotein D of herpes simplex virus type 1, selected by their reactivity with hyperimmune sera from mice.
Geerligs HJ; Kocken CH; Drijfhout JW; Weijer WJ; Bloemhoff W; Wilterdink JB; Welling GW; Welling-Wester S
J Gen Virol; 1990 Aug; 71 ( Pt 8)():1767-74. PubMed ID: 2167930
[TBL] [Abstract][Full Text] [Related]
7. The effect of adjuvants on the efficacy of a recombinant herpes simplex virus glycoprotein vaccine.
Sanchez-Pescador L; Burke RL; Ott G; Van Nest G
J Immunol; 1988 Sep; 141(5):1720-7. PubMed ID: 2842401
[TBL] [Abstract][Full Text] [Related]
8. Recombinant interleukin 2 as an adjuvant for vaccine-induced protection. Immunization of guinea pigs with herpes simplex virus subunit vaccines.
Weinberg A; Merigan TC
J Immunol; 1988 Jan; 140(1):294-9. PubMed ID: 2826591
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1.
Wang K; Tomaras GD; Jegaskanda S; Moody MA; Liao HX; Goodman KN; Berman PW; Rerks-Ngarm S; Pitisuttithum P; Nitayapan S; Kaewkungwal J; Haynes BF; Cohen JI
J Virol; 2017 Oct; 91(19):. PubMed ID: 28701403
[TBL] [Abstract][Full Text] [Related]
10. The proportion of herpes simplex virus-specific cytotoxic T lymphocytes (Tc) that recognize glycoprotein C varies between individual mice and is dependent on the form of immunization.
Martin S; Mercadal CM; Weir JP; Rouse BT
Viral Immunol; 1993; 6(1):21-33. PubMed ID: 8386515
[TBL] [Abstract][Full Text] [Related]
11. Coexpression of interleukin-2 enhances the immunization effect of a DNA vaccine expressing herpes simplex 1 glycoprotein D.
Li WR; Niu B; Wang JW; Feng ZJ; Wang DX
Acta Virol; 2006; 50(4):251-6. PubMed ID: 17177610
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of recombinant herpes simplex virus 1 glycoprotein D candidate vaccines in mice.
Durmanová V; Mosko T; Sapák M; Kosovský J; Rezuchová I; Buc M; Rajcáni J
Acta Microbiol Immunol Hung; 2006 Dec; 53(4):459-77. PubMed ID: 17278713
[TBL] [Abstract][Full Text] [Related]
13. Protective immunity against herpes simplex virus (HSV) type 1 following oral administration of recombinant Salmonella typhimurium vaccine strains expressing HSV antigens.
Karem KL; Bowen J; Kuklin N; Rouse BT
J Gen Virol; 1997 Feb; 78 ( Pt 2)():427-34. PubMed ID: 9018066
[TBL] [Abstract][Full Text] [Related]
14. The influence of different adjuvants on the immune response to a synthetic peptide comprising amino acid residues 9-21 of herpes simplex virus type 1 glycoprotein D.
Geerligs HJ; Weijer WJ; Welling GW; Welling-Wester S
J Immunol Methods; 1989 Nov; 124(1):95-102. PubMed ID: 2553820
[TBL] [Abstract][Full Text] [Related]
15. Regulation of expression of herpes simplex virus (HSV) glycoprotein D in vaccinia recombinants affects their ability to protect from cutaneous HSV-2 disease.
Wachsman M; Aurelian L; Smith CC; Perkus ME; Paoletti E
J Infect Dis; 1989 Apr; 159(4):625-34. PubMed ID: 2538519
[TBL] [Abstract][Full Text] [Related]
16. The effect of immunization with herpes simplex virus glycoprotein D fused with interleukin-2 against murine herpetic keratitis.
Inoue T; Inoue Y; Nakamura T; Yoshida A; Inoue Y; Tano Y; Shimomura Y; Fujisawa Y; Aono A; Hayashi K
Jpn J Ophthalmol; 2002; 46(4):370-76. PubMed ID: 12225814
[TBL] [Abstract][Full Text] [Related]
17. Effect of immunization with herpes simplex virus type-1 (HSV-1) glycoprotein D (gD) plus the immune enhancer GPI-0100 on infection with HSV-1 or HSV-2.
Quenelle DC; Collins DJ; Marciani DJ; Kern ER
Vaccine; 2006 Mar; 24(10):1515-22. PubMed ID: 16288820
[TBL] [Abstract][Full Text] [Related]
18. Intranasal immunization of mice with herpes simplex virus type 2 recombinant gD2: the effect of adjuvants on mucosal and serum antibody responses.
Ugozzoli M; O'Hagan DT; Ott GS
Immunology; 1998 Apr; 93(4):563-71. PubMed ID: 9659230
[TBL] [Abstract][Full Text] [Related]
19. Baculovirus-expressed herpes simplex virus type 2 glycoprotein D is immunogenic and protective against lethal HSV challenge.
Landolfi V; Zarley CD; Abramovitz AS; Figueroa N; Wu SL; Blasiak M; Ishizaka ST; Mishkin EM
Vaccine; 1993; 11(4):407-14. PubMed ID: 8385842
[TBL] [Abstract][Full Text] [Related]
20. Genetic immunization against herpes simplex virus. Protection is mediated by CD4+ T lymphocytes.
Manickan E; Rouse RJ; Yu Z; Wire WS; Rouse BT
J Immunol; 1995 Jul; 155(1):259-65. PubMed ID: 7602102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
